5 Best Defensive Stocks To Buy Right Now

Just a week ago the stock market was looking quite vulnerable as most of the major averages closed near their lows last Friday, April 11. There were signs of heavy selling, so I concluded last week that ��n a short-term basis, the market is getting oversold, so we should see a bounce this week. Unless it is quite strong, it will likely be an opportunity to become more defensive and raise some cash.��/p>

The higher close last Monday signaled the rebound was indeed underway and made Wednesday�� action pivotal as a sharply lower close would have signaled that the rebound was over and that investors should prepare for a further decline.

Instead, Janet Yellen�� clarifying comments at the Economic Club of New York seemed to calm the markets and bring in more buyers. She made it clear that the Fed would keep rates low as long as needed to be sure the recovery stayed on track.

She also seemed more worried about deflation than inflation as she said ��nflation persistently below 2% could pose risks to economic performance.��The Fed continues to think that the recent soft data is due in part to the very hard winter.

Top 5 Integrated Utility Stocks For 2015: Mylan Inc (MYL)

Mylan Inc. (Mylan), incorporated in 1970, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company operates a specialty business, which is focused on respiratory, allergy and psychiatric therapies. Through Mylan Laboratories Limited, an Indian subsidiary, it manufactures and supply active pharmaceutical ingredient (API) for its own products and pipeline, as well as for third parties. On December 23, 2011, Mylan completed the acquisition of rights to develop, manufacture and commercialize a generic equivalent to GlaxoSmithKline�� Advair Diskus and Seretide Diskus incorporating Pfizer Inc.��, (Pfizer) dry powder inhaler delivery platform (the Respiratory Delivery Platform). In February 2012, Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to the Company.

As of December 31, 2011, Mylan marketed a global portfolio of approximately 1,100 different products covering a range of therapeutic categories. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids. In addition, it focuses on transdermal patches, high potency formulations, injectables, controlled release and respiratory delivery products. Mylan operates in two segments: Generics and Specialty. Its revenues are derived from the sale of generic and branded generic pharmaceuticals, specialty pharmaceuticals and API. Its generic pharmaceutical business is conducted in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA), and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited, which is included within the Asia Pacific region in its Generi! cs segment. Its specialty pharmaceutical business is conducted by Dey Pharma, L.P. (Dey).

Generics Segment

The Company sales in the United States are derived through its wholly owned subsidiary Mylan Pharmaceuticals Inc. (MPI), its primary United States pharmaceutical research, development, manufacturing, marketing and distribution subsidiary, as well as through Mylan Institutional (MI). MPI�� net revenues are derived from the sale of solid oral dosage and transdermal patch products. MI�� net revenues are derived from the sale of its unit dose and injectable product offerings. In the United States, it has product portfolios consisting of approximately 340 products, of which approximately 305 are in capsule or tablet form in an aggregate of approximately 740 dosage strengths. Included in these totals are approximately 40 extended release products in a total of approximately 105 dosage strengths. Also included in it�� the United States product portfolio are four transdermal patch products in a total of 18 dosage strengths, which are developed and manufactured by Mylan Technologies, Inc. (MTI), its wholly owned transdermal technology subsidiary, and marketed and distributed by MPI.

The Company�� North America revenues also include those generated by its wholly owned subsidiary Mylan Pharmaceuticals ULC (MPC), which markets generic pharmaceuticals in Canada. MPC offers a portfolio of approximately 115 products in an aggregate of approximately 250 dosage strengths. Its generic pharmaceutical sales in EMEA are generated by its wholly owned subsidiaries in Europe, through which it has operations in 21 countries.

In France, through the Company�� subsidiary Mylan S.A.S., it markets a retail portfolio of approximately 215 products in an aggregate of approximately 455 dosage strengths. In Italy, it markets through its subsidiary Mylan S.p.A. a portfolio of approximately 150 products in an aggregate of approximately 285 dosage strengths. In Italy, it h! as market! share, based on value and volume, in the company-branded generic retail prescription market. In Spain, it markets through its subsidiary Mylan Pharmaceuticals S.L. a portfolio of approximately 100 products in an aggregate of approximately 220 dosage strengths. In Germany, it markets through its subsidiary Mylan dura a portfolio of approximately 150 products in an aggregate of approximately 330 dosage strengths. In the United Kingdom, it offers a product portfolio of approximately 175 products in an aggregate of approximately 315 dosage strengths. It markets generic pharmaceuticals in Asia Pacific through subsidiaries in Australia, New Zealand, India, Japan and Taiwan.

In Australia, the Company offers a portfolio of approximately 170 products in an aggregate of approximately 440 dosage strengths. Mylan Seiyaku, its wholly owned Japanese subsidiary, offers a portfolio of more than 380 products in an aggregate of approximately 500 dosage strengths. At Mylan Laboratories Limited, its dosage business produces antiretroviral (ARV) products, which are sold outside of India, and other finished dosage form (FDF) products, which are sold to third parties by other Mylan operations globally. In addition, Mylan Laboratories Limited offers a line of FDF products in the ARV market and manufactures non-ARV FDF products that are marketed by Mylan.

Specialty Segment

The Company�� specialty pharmaceutical business is conducted through Dey. Dey�� portfolio consists of branded specialty injectable, nebulized and transdermal products for life-threatening conditions. Dey�� revenues are derived through the sale of the EpiPen Auto-Injector. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector that has been sold in the United States and internationally.

Advisors' Opinion:

• [By Jonas Elmerraji]

  We're seeing the exact same price setup in shares of Mylan (MYL) right now. MYL has been one of the best-in-breed pharma stocks over the course of 2013, rallying more than 50% between January's first open and yesterday's close, and with shares approaching trendline support again, this stock looks primed for a bounce.

  Mylan's channel has provided a high-probability range for this stock's price action all the way since the summer. In fact, it's been more than high-probability; it's been textbook over that time.

  The 50-day moving average has been a stellar proxy for support all the way up Mylan's channel, so it's the perfect place to put a protective stop after the bounce in shares. Relative strength continues to be outsized in MYL right now – that means that this stock is statistically more likely to continue to beat the S&P 500 for the next 10 months. Wait for the bounce off of support before you buy...

• [By Laura Brodbeck]

  Thursday

  Earnings Expected From: Barrick Gold Corporation (NYSE: ABX), Newmont Mining Corporation (NYSE: NEM), Mastercard Incorporated (NYSE: MA), Mylan, Inc (NASDAQ: MYL), Time Warner Cable Inc. (NYSE: TWC) Economic Releases Expected: Chinese manufacturing PMI, South Korean trade balance, US Personal income, Italian PPI, eurozone unemployment rate, French consumer spending, Spanish current account

  Friday

5 Best Defensive Stocks To Buy Right Now: Grifols SA (GRFS)

Grifols SA is a Spain-based company engaged in the healthcare sector. The Company is involved in the research, development, manufacturing and marketing of medical solutions for hospitals, which include plasma-derived therapies, as well as diagnosis and pharmaceutical products. Its activities are structured in four segments: Bioscience, which focuses on the research for obtaining new therapies and solutions aimed at patients who suffer from illnesses stemming from plasma deficits; Diagnostic, which comprises the research, development and marketing of diagnostic products for clinical laboratories, Hospital, which offers ready-to-use pharmaceutical preparations and products for clinical nutrition; and Raw Materials, which includes sales of biological products and services. The Company is a parent of Grupo Grifols. In March 2013, the Company acquired a 60% stake in Progenika Biopharma SA. On January 9, 2014, the Company acquired a diagnostic unit from Novartis International AG. Advisors' Opinion:

• [By Philip Springer]

  What’s more, earnings estimates for 2014 by Wall Street analysts have increased for seven of the 10 companies over the last three months. Amgen’s are down slightly and those for Celgene and Novo Nordisk are unchanged.
  
  Two of the 10 stocks currently are in the PF Growth Portfolio. Another, Allergan, was sold for a 75 percent long-term gain since its initial recommendation.
  
  As of late February, the 10 stocks profiled carried market capitalizations of roughly $30 billion and up. Here are another four companies to watch: Grifols SA (NSDQ: GRFS), Jazz Pharmaceuticals PLC (NSDQ: JAZZ), Questcor Pharmaceuticals (NSDQ: QCOR) and Salix Pharmaceuticals (NSDQ: SLXP). Each of these four companies is generating rapid revenue and profit growth, and each stock carries a market capitalization of $5 billion or more.
  
  Have a happy and safe Fourth of July weekend!

• [By Monica Wolfe]

  Grifols SA (GRFS)

  Paulson�� fourth largest holding is in Grifols SA where he maintains 19,838,107 shares of the company�� stock. His holdings make up for 3.9% of his total portfolio as well as for 5.77% of the company�� shares outstanding.

• [By Monica Wolfe]

  Grifols SA (GRFS)

  Paulson�� fourth largest holding is in Grifols SA where he holds on to 19,786,279 shares of the company�� stock. His position in the company represents 4% of his total portfolio and 5.76% of the company�� shares outstanding.

5 Best Defensive Stocks To Buy Right Now: Apollo Group Inc.(APOL)

Apollo Group, Inc., through its subsidiaries, provides online and on-campus educational programs and services at the undergraduate, master?s, and doctoral levels. The company offers various degree programs in arts and sciences, business and management, criminal justice and security, education, health care, human services, nursing, psychology, and technology through its campus locations and learning centers in 40 states and the District of Columbia, and Puerto Rico, as well as through its online education delivery system. It also provides various degree programs in Chile and Mexico, and through online; financial services education programs, including Master of Science in three majors, as well as certification programs in retirement, asset management, and other financial planning areas; and training and education to professionals in the legal and finance industries through its schools in the United Kingdom and a network of offices in Europe. In addition, the company offers p rogram development, administration, and management consulting services comprising degree program design, curriculum development, market research, student admissions, and accounting and administrative services to private colleges and universities for their working learners? programs; and sells books and other publications. Apollo Group, Inc. was founded in 1973 and is based in Phoenix, Arizona.

Advisors' Opinion:

• [By Anna Prior]

  Among the companies with shares expected to actively trade in Wednesday’s session are Apollo Education Group Inc.(APOL), DFC Global Corp.(DLLR) and MannKind Corp.(MNKD)

• [By Bryan Murphy]

  While the given problems that are plaguing Corinthian Colleges Inc. (NASDAQ:COCO) are unique to that particular for-profit school today, the underpinnings for today's 62% implosion from COCO shares are just as big of a threat to the likes of Apollo Education Group Inc. (NASDAQ:APOL), Career Education Corp. (NASDAQ:CECO), and most other for-profit education names. In fact, those woes have been well documented for a while, and showing up each company's books for almost as long. Pictures tell the grim tale for CECO, APOL, and all the rest as effectively as any words could, so let's let the images of what's going on here do most of the talking, beginning with... Career Education Corp.

5 Best Defensive Stocks To Buy Right Now: Houston Wire & Cable Co (HWCC)

Houston Wire & Cable Company, incorporated in 1997, provides wire and cable and related services to the United States market. The Company offers its customers with a single-source solution for wire and cable, hardware and related services. The Company offers products in categories of wire and cable, including continuous and interlocked armor cable, control and power cable, electronic wire and cable, flexible and portable cords, instrumentation and thermocouple cable, lead and high temperature cable, medium voltage cable, premise and category wire and cable, wire rope and wire rope slings, as well as nylon slings, chain, shackles and other related hardware. It also offers private branded products, including its brand LifeGuard, a low-smoke, zero-halogen cable. On January 1, 2011, the acquired companies were merged into HWC Wire & Cable Company.

The Company�� products are used in repair and replacement, also known as maintenance, repair and operations (MRO), and related projects, larger-scale projects in the utility, industrial and infrastructure markets and a diverse range of industrial applications, including communications, energy, engineering and construction, general manufacturing, mining, construction, oilfield services, infrastructure, petrochemical, transportation, utility, wastewater treatment, marine construction and marine transportation. During the year ended December 31, 2011, the Company served approximately 6,000 customers.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Houston Wire & Cable (Nasdaq: HWCC  ) , whose recent revenue and earnings are plotted below.